Learning Hub

< BACK iPROLEPSIS digital ecosystem's architecture Oct 5, 2023 iPROLEPSIS ecosystem's architecture: a glimpse into technical progress One of the main objectives of the iPROLEPSIS project is to provide a digital health ecosystem to support healthcare professionals in disease screening, monitoring, and treatment while empowering individuals with/at risk of Psoriatic Arthritis with personalised insights and preventive interventions. In September 2023, the project’s technical partners introduced the first version of the iPROLEPSIS ecosystem architecture , including the initial technical specifications and product backlog. __________________ Amalia Ntemou from Netcompany-Intrasoft , consortium partner leading technical specification, system architecture and product backlog task within iPROLEPSIS, shares insights on the latest updates on the iPROLEPSIS ecosystem architecture. The first version of the iPROLEPSIS ecosystem's architecture and technical specifications has been defined. Can you explain the importance of this achievement in the project's development process? One of the main objectives of the iPROLEPSIS project is to provide a digital health ecosystem to support healthcare professionals in disease screening, monitoring, and treatment, while empowering individuals with/at risk of PsA with personalised insights and preventive interventions. The design of the architecture and the definition of functional and non-functional requirements are essential for the successful implementation of the iPROLEPSIS ecosystem as it constitutes a clear and comprehensive guide for partners’ development efforts. Various systems’ elements, components, connectors, processes and interactions are illustrated thereby enabling common understanding among project’s partners and adherence to common approaches and specifications that promote effective collaboration and delivery. A well-defined architecture with clear functional and non-functional requirements can be the basis for delivering sustainable solutions. What are the main components of the iPROLEPSIS digital ecosystem to be developed? The initial conceptual architecture of the iPROLEPSIS ecosystem consists of the miPROLEPSIS patient mobile app (including the embedded subcomponent/feature biAURA), the iPROLEPSIS healthcare professionals (HCP) web app , the cloud-based Data Management System , the AI-driven Lifestyle Recommendation Engine , the xAI-driven Models Engine and the Serious Games Suite . Finally, the operation of the entire system is supported by the Orchestration and Monitoring component . For whom is the iPROLEPSIS ecosystem specifically intended, and how does it cater to their unique needs? Patients are the primary users of the miPROLEPSIS patient app which is the tool for personalised disease monitoring. The miPROLEPSIS patient app operates as a tool for capturing data from sensors and wearable devices, as well as communicating feedback from the recommendation engine to the user. The miPROLEPSIS patient app incorporates additional applications/features (e.g., biAURA, keyboard etc.) for further monitoring of patients’ conditions, interventions and engagement hooks. Via the miPROLEPSIS HCP app, doctors and health care professionals are able to track their patients’ health status, review projections of the PsA progression, and utilise recommendations of optimised personalised suggestions towards a better management of PsA. Aggregated patients’ data about their health status, and outcomes of the xAI Models Engine are displayed intuitively and informatively to HCPs through dashboards. Doctors can monitor patients’ adherence to medical, dietary, and physical activity plans and issue warnings and notifications or adjust treatment regimens. In this way, accurate interventions are supported, while efficient and optimized management of PsA patients’ needs can be achieved and communicated to fellow colleagues and related stakeholders. What was the main focus while designing the iPROLEPSIS ecosystem architecture? The iPROLEPSIS digital health ecosystem serves as the enabler for personalised preventive care and the empowerment of citizens, patients and Healthcare Professionals (HCP). This emphasis on personalisation and empowerment guided the collection and definition of functional and non-functional requirements, as well as the internal architecture of components and technical specifications. Ultimately, these efforts led to the design of the ecosystem’s architecture. Have any methodologies been used in designing the iPROLEPSIS ecosystem architecture, and why is it important to use them? To organise the design and architecture of the iPROLEPSIS ecosystem, several established frameworks/methodologies were evaluated based on a thorough literature review in order to conclude to a framework that provides a holistic and comprehensive view of a software system’s architecture. Finally, we used a widely known methodology developed in 1995 by Kruchten , due to its ability to offer a structured approach to the system’s design, enabling multidisciplinary teams to represent different aspects of the system effectively and in detail. Utilising already established methodologies and following best practices, enhances efficiency, reduces risks, leads in better design decisions and contributes to overall success of the project. As the project progresses, how will the architecture and product backlog be refined and adapted during the development phases of the iPROLEPSIS? Development and establishment of the iPROLEPSIS digital health ecosystem is an ongoing process that runs approximately until the end of the project. Technical testing and verification of new versions of ecosystem’s components, as well as the monitoring of their performance and stability once released to users, have also been considered. The outcomes of development and monitoring processes will continuously populate the product backlog, representing the changing needs and priorities as the development of the components progresses. All updates and enhancements will lead to a refined version of the architecture and a fully operational iPROLEPSIS ecosystem. Stay tuned as we embark on this transformative journey towards a brighter future in Psoriatic Arthritis management! News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Handbook Handbook Understanding Psoriatic Arthritis Handbook Sections What is psoriatic arthritis? What causes psoriatic arthritis? What are the symptoms of psoriatic arthritis? How is psoriatic arthritis diagnosed? Read Sections Living with Psoriatic Arthritis Handbook Sections Work Sleep and fatigue Emotional wellbeing Read Sections Managing Psoriatic Arthritis Handbook Sections How is psoriatic arthritis treated? Non-pharmacological treatments Self-care and lifestyle Read Sections Intimacy, Reproductive Health and Family Life Handbook Sections Relationships and sex Fertility, pregnancy, and breastfeeding Read Sections Psoriatic Arthritis Handbook Handbook

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Intimacy, Reproductive Health and Family Life Handbook How will psoriatic arthritis affect me? RELATIONSHIPS AND SEX Psoriatic arthritis can present a number of challenges in a relationship, namely: reduce your enjoyment of sex and other activities you share with your partner; affect your mood and self-esteem; impact your ability to contribute to household and family related duties; lead to financial worries if your condition affects your ability to work. Although your relationship may change because of psoriatic arthritis, you should remember that most couples go through phases in their relationship that are more or less positive, depending on a number of factors such as stress, work-life balance, or other health conditions. See related Key Facts section h4.1 h4.3 Talking to your partner about any changes or challenges you may be facing is a great way to improve communication in the relationship and arrive at solutions to please both of you. If you are not in a relationship and worry about how your condition may affect your prospects of finding a romantic partner, especially if you have visible signs of the condition, keep in mind that most relationships develop gradually and that shared interests are more important than physical considerations. While sex will not make your psoriatic arthritis worse, it can sometimes be painful when you move an affected joint. Besides the physical aspect, psoriatic arthritis may decrease your sex drive, affect your self- confidence, or make you feel less attractive. Psoriatic arthritis can sometimes lead to a dry vagina, and thus to uncomfortable sex. If this is the case, water-based lubricants can help you and/or your partner. Oil-based lubricants may irritate your skin or damage condoms. To help you overcome difficulties with sex, you should: talk openly with your partner about your physical and/or emotional concerns; keep active as physical exercise can help you strengthen your muscles and support your joints; take painkillers approximately one hour before having sex to minimise pain; try different positions and use cushions, pillows, or furniture to support your body; remember that there are multiple ways to achieve sexual satisfactions, such as kissing, caressing, mutual masturbation, oral stimulation, or even sex aids such as vibrators. See related Key Facts section FERTILITY, PREGNANCY, AND BREASTFEEDING If you are planning to start a family, you should discuss your treatment plan with your rheumatologist, as some medications are not safe in pregnancy. It is completely normal to feel concerned about the effect of your condition on your ability to start a family. People with arthritis may take slightly longer to become pregnant. It is best to try for a baby when your condition is not very active. There is a genetic contribution to psoriatic arthritis, that is, the presence of certain genes makes a person more likely to develop the condition. However, this is not a strictly hereditary condition. There are many factors involved in the development of psoriatic arthritis, not just the genes inherited from parents. Therefore, in the vast majority of cases the chances of passing it on to your children are relatively low. FERTILITY In women, there is no evidence to support that psoriatic arthritis affects fertility (51). However, a recent study indicated that untreated inflammatory arthritis, such as psoriatic arthritis, may decrease male fertility (52). In both women and men, fertility does decrease with age or may be affected by other health conditions. h4.2 Therefore, some people living with psoriatic arthritis will need fertility treatments. If your psoriatic arthritis is under control, there should be no problem to initiate fertility treatments. Discuss any plans for fertility treatments with your rheumatologist. They can offer specific advice, review your treatment plan, and liaise with the medical team responsible for your fertility treatment. See related Key Facts section PREGNANCY AND BREASTFEEDING Discuss your plans to start a family with your rheumatologist so that your treatment plan can be adjusted. If you become pregnant unexpectedly, talk to your rheumatologist as soon as possible. All women get aches and pains during pregnancy. As the baby grows, you may feel additional strain on some of your joints, especially on your hips and knees. While there is not a lot of information on the effects of pregnancy in psoriatic arthritis, studies have shown that the majority of women living with rheumatoid arthritis experience some form of symptom improvement during pregnancy. However, some women will have a flare after giving birth. Psoriatic arthritis usually does not affect delivery and you can still give birth through your vagina. If you are considering a caesarean, you should discuss this with your doctors (rheumatologist and obstetrician). It may be necessary to stop some of your medications before the surgery. You should continue anti-rheumatic drugs that are safe in pregnancy during pregnancy and breastfeeding. This will reduce your chances of any complications during pregnancy and will make flares less likely after giving birth. Many mothers feel sad, tearful, or anxious in the first two weeks after having a baby. However, if these symptoms last for longer or start later on, you may have post-natal depression, which affects 1 in 10 women after giving birth. It is important to seek medical help if you feel this way. See related Key Facts section h4.4 Remember that you are not alone. If you need extra support, please speak to your GP or Health Visitor. More information can be found below: NHS Mental Health Services https://www.nhs.uk/nhs-services/mental-health-services/ NHS Postnatal Depression https://www.nhs.uk/mental-health/ conditions/post-natal-depression/overview/ Be kind to your joints and your mind. See related Key Facts Previous page Next page

Clinical experts team Gail Heritage University of Oxford Position Senior Research Manager What is your role in iPROLEPSIS? UK PDPID coordinating center Manager What are your main activities in the project? UK Study manager What is your motivation? Contribution to clinical research to enhance patient experiences and disease outcomes. Francesca Levi-Schaffer The Hebrew University of Jerusalem, Israel Position Professor What is your role in iPROLEPSIS? Researcher What are your main activities in the project? To try to understand the passage from psoriasis to psoriatic arthritis by evaluating in skin biopsies vascularization, mast cell presence and to correlate this with involved joint vascularization What is your motivation? I would like to discover the connections between skin and joints and find a drug/s that can inhabit this progression Laura Coates Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Position NIHR Research Professor What is your role in iPROLEPSIS? Lead for WP5 (clinical studies) What are your main activities in the project? I oversee all of the clinical studies within the consortium. What is your motivation? I am a rheumatologist who has worked in research in psoriatic arthritis for around 20 years. My interest is in improving outcomes for people living with psoriatic arthritis and I believe that work in this project can help us to predict, monitor and understand the disease better in day to day clinics. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

< BACK Highlights from PETRA 2024 Jul 1, 2024 The iPROLEPSIS Exergames Introduced at PETRA 2024 The iPROLEPSIS Exergames were introduced and received very positively by the audience at PETRA 2024, a scientific interdisciplinary conference held on 26-28 June 2024 in Crete, Greece. Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes Abstract: Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Here, within the Horizon Europe iPROLEPSIS project that targets Psoriatic Arthritis (PsA), we describe the design process of Exergames to address PsA symptoms, including morning stiffness, impaired finger/hand and wrist functionality, and motor asymmetry. From a methodological point of view, the storyboarding technique was adopted to facilitate the visualization of the proposed Exergame scenarios, including the graphical user interface, interactive game elements, narratives, characters, and contexts related to the PsA condition. This approach has been implemented within an agile game development methodology, which includes gathering feedback early on to iteratively refine both the game ideas and prototype. Informed by the results of the game design via two agile sessions incorporating 25 participants (PsA patients, clinicians, technology developers, facilitators/observers), the current efforts are focused on developing the game prototypes and corresponding mock-ups, preparing them for upcoming clinical validation trials. The Exergames development lays the groundwork for an innovative framework to improve gross and fine motor symptoms in PsA patients. This framework could inform healthcare providers and policymakers about its potential inclusion in routine PsA management. Read the full publication: https://dl.acm.org/doi/10.1145/3652037.3663939 1/3 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 5 Jul 10, 2024 Discover Insights from Clinicians, Collaborative Efforts, and Key Events Welcome to the fifth edition of the iPROLEPSIS project newsletter. In this issue, we bring you insightful interviews with clinicians specialising in psoriatic arthritis, insights into recent clustering and networking activities, and reflections on key past events. iPROLEPSIS_Newsletter No. 5 .pdf Download PDF • 8.01MB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the COMFORT-EU Plenary Meeting May 19, 2025 Strengthening Collaboration in AI for Healthcare Dr. Vasileios Charisis (Aristotle University of Thessaloniki) recently took part in the 2nd Plenary Meeting of the COMFORT-EU project (15–16 May 2025), where he presented the iPROLEPSIS project and introduced our work on a Trustworthy AI framework for healthcare. Meetings like this offer a valuable opportunity to connect with other research teams, share knowledge, and explore ways to collaborate. In the fast-evolving field of AI in healthcare , collaboration is essential — helping us learn from each other and develop better, safer solutions for real-world use. We are excited to continue working with COMFORT-EU and other Horizon Europe projects to drive innovation that benefits both science and society. 2.jpg 2.jpg 1/1 PREVIOUS NEXT

iPROLEPSIS project will perform four different clinical studies in four different counties. Learn more about clinical studies by visiting iprolepsis.eu. About clinical studies iPROLEPSIS will perform four different clinical studies: 1. iPROLEPSIS-PDPID PsA digital phenotyping and inflammation drivers study. 2. iPROLEPSIS-MOJMI Mast cells and optoacoustics-enabled joint and microvascular imaging study. 3. iPROLEPSIS-IDBV Inflammation digital biomarkers validation study. 4. iPROLEPSIS-PPIDC Prevention of PsA inflammation through digital care: an intervention study. Clinical studies will be conducted in 5 countries: Netherlands UK Portugal Greece Germany Clinical studies PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) Development cohort of smartphone and smartwatch-based, AI-driven digital biomarkers for remote assessment and monitoring of people with psoriatic arthritis. Measure To develop novel smartphone- and smart device (belt, ring, camera) digital biomarkers for the assessment of inflammatory symptoms with special focus on the recognition of changes in movement patterns, pain, fatigue, morning stiffness in comparison to the gold standard – medical evaluation by clinical evaluation of the joints, tendons and skin. Predict To predict the change from uninflamed to inflamed using three triggers that may cause longstanding inflammation in psoriatic arthritis patients at risk for flare. Those three triggers are stress, mechanical stress and changes in the gut microbiome. OBJECTIVES Primary objectives to provide accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch[1] based, AI-driven digital biomarker system in the detection of PsA specific inflammation; to predict accurate, factual and clinically relevant PsA specific inflammation. Secondary objectives to determine interperson reliability of the AI-driven digital biomarker system; to determine construct validity against clinical assessment of inflammation; to determine construct validity against patient assessment of inflammation; to determine clinically relevant changes in the AI-driven digital biomarker system; to determine minimal detectable difference in the AI-driven digital biomarker system; to assess the interperson variation of stress, mechanical stress and changes in gut microbiome on the occurrence of inflammation; to evaluate the compliance and satisfaction of the users with the smartphone and smartwatch-based, AI[1] driven digital monitoring system. The study is designed to develop a new way of measuring inflammation in patient with psoriatic arthritis. Definition of novel optoacoustic biomarkers of psoriasis and psoriatic arthritis (iPROLEPSIS-MOJMI) Mast cells and optoacoustics-enabled joint and microvascular imaging (iPROLEPSIS-MOJMI) study. The proposed multiscale (mesoscopic with RSOM and macroscopic with MSOT) approach aims at exploring and defining novel image-based biomarkers in order to describe the pathophysiological changes characterizing the disease and predict the transition from PsO to PsA. In other words, the unique multiscale nature of optoacoustics is expected to render skin microvasculature a window to later systemic (joint) effects of psoriasis and, thus, improve the prognosis in future patients with PsO. OBJECTIVES Primary objectives To define novel inflammatory mast cell, MSOT- and RSOM extracted biomarkers in patients with PsO/PsA. To quantify the changes of the novel inflammatory mast cell, MSOT- and RSOM-extracted biomarkers' with increasing disease severity. Secondary objectives To reveal correlations among the mast cells and the MSOT-and RSOM-extracted inflammatory biomarkers in patients with PsO/PsA. To define a novel index derived from mast cells, MSOT- and RSOM-based features to enable the early detection of PsA in patients with PsO or high risk for developing PsO. Inflammation digital biomarkers validation study (iPROLEPSIS-IDBV) Finding people that will convert from healthy to inflamed is a difficult task in Immune Mediated Inflammatory Disease (IMID). Initial symptoms look just like any other musculoskeletal disorder such as back pain, finger pain or achilles tendon problems. Over time symptoms can go either temporarily away, become chronic or become so severe that doctor care is needed. Early identification of people with IMID would greatly benefit their quality of live, keeps them at work and prevents high health care cost due to expensive medication. Digital biomarkers will give us for the first time the ability to study the conversion from musculoskeletal disorder to immune mediated inflammatory joint and tendon disease. The aim of this study to validate our digital biomarkers findings in PsA in psoriasis patients. OBJECTIVES Primary objectives to validate accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch-based, AI-driven digital biomarker system in the detection of IMID specific joint or tendon inflammation. Secondary objectives to evaluate take up and acceptability of the digital biomarker in the wild; to evaluate the impact of missing data in detecting inflammation; to assess the number of false positives when data is captured in the wild; to assess the interperson variation of stress and mechanical stress. The aim is to identify inflammation with a software based medical device. This software will consist of an algorithm analysing data collected in the wild via smart devices: phone, watch, ring. Prevention of PsA inflammation through digital care: an intervention study (iPROLEPSIS-PPIDC) This study blends the findings of the newly developed digital biomarkers, the early findings of the triggers: stress, mechanical stress and changes in microbiome from PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID), to provide a personalised approach to deal with the triggers with state-of-the-art interventions. OBJECTIVES Primary objectives In PsA patients with low disease activity a personalised intervention on food, physical activity and stress based on a personal profile of stress, mechanical stress and microbiome will be compared to usual care on inflammation development as detected by the newly developed digital biomarker system and clinical examination. Secondary objectives to evaluate take up and acceptability of the digital biomarker and intervention as part of normal medical treatment among patients, doctors and nurses; to assess compliance with the personalised intervention.

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts keyfacts 1 Understanding Psoriatic Arthritis Learn what psoriatic arthritis is, how it’s connected to psoriasis, what symptoms to look out for, how it’s diagnosed, and how to recognise a flare. f1.1 f1.2 See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f1.3 f1.5 F1.4 keyfacts 2 Managing Psoriatic Arthritis: Treatments and Lifestyle Learn how psoriatic arthritis is treated through medications, non-pharmacological treatments, and everyday lifestyle choices that support health and wellbeing. See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f2.1 f2.2 f2.3 f2.4 f2.5 keyfacts 3 Living with Psoriatic Arthritis Everyday tips for balancing work, improving sleep, managing fatigue, and supporting mental wellbeing. f3.1 See related Handbook section See related Handbook section See related Handbook section See related Handbook section f3.2 f3.3 f3.4 key facts 4 Intimacy, Reproductive Health and Family Life Understanding how psoriatic arthritis may affect relationships, sexual and reproductive health, and family planning decisions. See related Handbook section See related Handbook section See related Handbook section See related Handbook section f4.1 f4.2 f4.3 f4.4

< BACK Advancing Digital Health Solutions: Updates on User Research and Co-Creation Nov 20, 2023 Navigating the Development of PDPID-App, Insights from Co-Creation Sessions Updates on user research and co-creation The current status of user research and co-creation involves a dedicated focus on advancing the development of the PDPID-app , scheduled for delivery before January 2023. In early October 2023, Erasmus MC ( EMC) conducted a co-creation session with patient partners to assess the general looks and feel of the User Interface (UI) and identify points to improve the app's usability. In apps used for medical data collection, it is of utmost importance that users know what is expected of them. Furthermore, users should be engaged with the app to a level that minimises missing data. Following this, bi-weekly meetings with patient partners were established to maintain alignment with their ideas. Furthermore, project partner FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) is developing storyboards for the personalised gaming suite . Three co-creation sessions have been executed: one with healthcare professionals and two with patient partners. Additionally, project partners The Centre for Research and Technology Hellas (CERTH) and FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) have been working with the clinical partners to identify movements for the video analysis tasks that will be included in the iPROLEPSIS-PDPID study. Multiple hand gestures and full-body movements have been identified for further assessment. Key take-away messages The development of the Digital health tools is still at an early stage. However, several take-away messages from the discussions about the PDPID app are : The general looks and UI of the miPROLEPSIS app have been approved by the patient partners. Even though the PDPID-app is a data-collection app for research purposes, patients find it of utmost importance that they can review their own data entries. Participants indicated that the app needs to improve its’ visual cues of when they need to perform certain activities. Take-away messages from the discussions about personalised gaming suite development: Smart games meant for disease management should be highly tailored to the capabilities of the patients. Gaming is for patients a way of relaxation, any game designed should not incorporate any stressful factors. Patient partners expressed interest in the proposed gaming categories. Future steps Future steps involve initiating a round of user testing for the PDPID version of the miPROLEPSIS app to validate designs with patients not involved in the development process. Subsequently, attention will shift to developing recommendation systems for physical activity and diet, incorporating insights from experts in the field (occupational therapists, physical therapists & nutritionists) and patients themselves. For the personalised gaming suite, the completion of the storyboard is planned for the end of December 2023, when the development of the first prototypes will follow. mIPROLEPSIS app.png mIPROLEPSIS app.png 1/1 PREVIOUS NEXT

< BACK The miPROLEPSIS Joint Landmarker App Now Available for Android Devices on Google Play Store Sep 25, 2024 A New Tool for Assessing Physical Function in Psoriatic Arthritis As of 25 September 2024, the miPROLEPSIS Joint Landmarker app is available for Android devices on the Google Play Store. This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. miPROLEPSIS Joint Landmarker - Apps on Google Play 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Kick-Off Meeting Jan 8, 2023 iPROLEPSIS, a four-year Horizon Europe project on AI-enabled Psoriatic Arthritis screening, monitoring, and care, kicked off. iPROLEPSIS, a four-year H orizon Europe project on AI-enabled Psoriatic Arthritis screening, monitoring, and care, kicked off. Our consortium partners met in Thessaloniki, Greece, and during a two-day event laid the groundwork for this exciting research and innovation venture. The focus was placed on the four clinical studies that will be conducted in the project. News & Events iPROLEPSIS.png News & Events iPROLEPSIS.png 1/1 PREVIOUS NEXT